Adverse event totals15

The totals the trial posted for each group.

1 to 15 of 15

Total	Group	Affected	At risk
Total, all-cause mortality	Cebranopadol 100 µg	0	64
Total, all-cause mortality	Cebranopadol 300 µg	0	61
Total, all-cause mortality	Cebranopadol 600 µg	0	62
Total, all-cause mortality	Pregabalin	0	65
Total, all-cause mortality	Matching Placebo	0	62
Total, other adverse events	Cebranopadol 100 µg	47	64
Total, other adverse events	Cebranopadol 300 µg	50	61
Total, other adverse events	Cebranopadol 600 µg	53	62
Total, other adverse events	Pregabalin	49	65
Total, other adverse events	Matching Placebo	43	62
Total, serious adverse events	Cebranopadol 100 µg	1	64
Total, serious adverse events	Cebranopadol 300 µg	2	61
Total, serious adverse events	Cebranopadol 600 µg	4	62
Total, serious adverse events	Pregabalin	1	65
Total, serious adverse events	Matching Placebo	2	62

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01939366/event-totals